Zacks Maintains Strong $4.44 Price Target for Pressure BioSciences Inc. (PBIO)
Zacks has reiterated support for their initial $4.44 share price target for Pressure BioSciences PBIO’s fundamentals remain strong, with record sales of consumables and increased revenue from products and services over same quarter previous year Company anticipates doubling of total revenue in 2020, driven by anticipated sales of their proprietary BaroShear K45 System, which provides the CBD market with much-needed, superior water-soluble nanoemulsions of CBD Oil Zacks Small Cap Research, a division of Zacks Investment Research, has announced that they are maintaining their strong $4.44 share price target originally stated in their initial coverage of Pressure BioSciences Inc. (OTCQB: PBIO),…